These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28611861)

  • 1. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data.
    Yanai H; Hakoshima M; Adachi H; Kawaguchi A; Waragai Y; Harigae T; Masui Y; Kakuta K; Hamasaki H; Katsuyama H; Kaga T; Sako A
    J Clin Med Res; 2017 Jul; 9(7):605-612. PubMed ID: 28611861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters in Patients With Type 2 Diabetes: A Chart-Based Analysis.
    Katsuyama H; Hamasaki H; Adachi H; Moriyama S; Kawaguchi A; Sako A; Mishima S; Yanai H
    J Clin Med Res; 2016 Mar; 8(3):237-43. PubMed ID: 26858798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis.
    Akbari A; Rafiee M; Sathyapalan T; Sahebkar A
    J Diabetes Res; 2022; 2022():7520632. PubMed ID: 35224108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
    Katsiki N; Mikhailidis DP; Theodorakis MJ
    Curr Pharm Des; 2017; 23(10):1522-1532. PubMed ID: 28088910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors Reduce Prandial Insulin Doses in Type 2 Diabetic Patients Treated With the Intensive Insulin Therapy.
    Hakoshima M; Yanai H; Kakuta K; Adachi H
    J Clin Med Res; 2018 Jun; 10(6):493-498. PubMed ID: 29707091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge.
    Provenzano M; Pelle MC; Zaffina I; Tassone B; Pujia R; Ricchio M; Serra R; Sciacqua A; Michael A; Andreucci M; Arturi F
    Front Med (Lausanne); 2021; 8():654557. PubMed ID: 34150796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Call for a New Paradigm for Diabetes Care in the Era of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i).
    Kim SH; Chang TI; Mahaffey KW
    Cardiol Ther; 2020 Dec; 9(2):219-225. PubMed ID: 32661684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of exercise training and sodium-glucose cotransporter-2 inhibition improves glucose tolerance and exercise capacity in a rodent model of type 2 diabetes.
    Linden MA; Ross TT; Beebe DA; Gorgoglione MF; Hamilton KL; Miller BF; Braun B; Esler WP
    Metabolism; 2019 Aug; 97():68-80. PubMed ID: 31132381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus.
    Unnikrishnan AG; Kalra S; Purandare V; Vasnawala H
    Indian J Endocrinol Metab; 2018; 22(6):837-842. PubMed ID: 30766827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real-world retrospective observational study.
    Imre E; Gunhan HG; Erel P; Ustay O
    Minerva Endocrinol (Torino); 2023 Sep; 48(3):295-304. PubMed ID: 33979071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.
    Seko Y; Sumida Y; Tanaka S; Mori K; Taketani H; Ishiba H; Hara T; Okajima A; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Kanemasa K; Yasui K; Imai S; Shimada K; Itoh Y
    Hepatol Res; 2017 Sep; 47(10):1072-1078. PubMed ID: 27925353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
    Atageldiyeva K; Fujita Y; Yanagimachi T; Mizumoto K; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
    PLoS One; 2016; 11(6):e0157672. PubMed ID: 27327650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
    Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
    Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic-associated fatty liver disease.
    Mino M; Kakazu E; Sano A; Katsuyama H; Hakoshima M; Yanai H; Aoki Y; Imamura M; Yamazoe T; Mori T; Yoshio S; Inoue J; Masamune A; Kanto T
    Hepatol Res; 2023 Jul; 53(7):618-628. PubMed ID: 36905232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Efficacy and Safety Among Sodium-glucose Cotransporter-2 Inhibitors in Type 2 Diabetes - Results from a Retrospective Single-centre Study.
    Baruah MP; Kalra S
    Eur Endocrinol; 2019 Aug; 15(2):113-118. PubMed ID: 31616503
    [No Abstract]   [Full Text] [Related]  

  • 20. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.